1345847-71-3

Basic information

• Product Name: METHYL 1-[(4-FLUOROPHENYL)CARBAMOYL]CYCLOPROPANECARBOXYLATE
• Synonyms: METHYL 1-[(4-FLUOROPHENYL)CARBAMOYL]CYCLOPROPANECARBOXYLATE;methyl 1-((4-fluorophenyl)carbamoyl)cyclopropane-1-carboxylate
• CAS NO: 1345847-71-3
• Molecular Formula: C₁₂H₁₂FNO₃
• Molecular Weight: 237.2269832
• EINECS: -0
• Mol File: 1345847-71-3.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: METHYL 1-[(4-FLUOROPHENYL)CARBAMOYL]CYCLOPROPANECARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 1-[(4-FLUOROPHENYL)CARBAMOYL]CYCLOPROPANECARBOXYLATE(1345847-71-3)
• EPA Substance Registry System: METHYL 1-[(4-FLUOROPHENYL)CARBAMOYL]CYCLOPROPANECARBOXYLATE(1345847-71-3)

Safety Data

• Hazardous Substances Data: 1345847-71-3(Hazardous Substances Data)

Usage

General Description

Methyl 1-[(4-fluorophenyl)carbamoyl]cyclopropanecarboxylate is a chemical compound that belongs to the class of carbamate esters. It is known for its potential use in pharmaceutical research and development, specifically in the synthesis of new drugs and active pharmaceutical ingredients. METHYL 1-[(4-FLUOROPHENYL)CARBAMOYL]CYCLOPROPANECARBOXYLATE is characterized by its unique three-membered cyclopropane ring, which provides structural diversity and potential biological activity. Its fluoro-substituted phenyl group and carbamoyl functionality also offer opportunities for designing and studying new compounds with possible medicinal properties. Additionally, the methyl ester group can contribute to its solubility and metabolic stability, making it a valuable building block in synthetic chemistry and drug discovery.

Upstream product

• 113020-21-6 1,1-cyclopropanedicarboxylic acid monomethyl ester 
• 371-40-4 4-fluoroaniline 
• 67-56-1 methanol 
• 849217-48-7 ((4-fluorophenyl)carbamoyl)cyclopropanecarboxylic acid 
• 6914-71-2 dimethyl 1,1-cyclopropanedicarboxylate 

Downstream Products

• 849217-48-7 ((4-fluorophenyl)carbamoyl)cyclopropanecarboxylic acid 
• 928038-31-7 N-{4-[(2-Aminopyridin-4-yl)oxy]-2-fluorophenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 928038-40-8 N-(4-{[2-Aminopyridin-4-yl)oxy]-2,5-difluorophenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 1345848-28-3 (S)-1-[4-(2,5-difluoro-4-{[1-(4-fluorophenylcarbamoyl)cyclopropanecarbonyl]amino}phenoxy)pyridin-2-ylcarbamoyl]ethyl acetate 
• 1345848-30-7 (S)-N-(2,5-difluoro-4-((2-(2-hydroxypropanamido)pyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 1345848-32-9 N-(2,5-difluoro-4-((2-(2-fluoro-2-methylpropanamido)pyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 1345847-77-9 N-[4-(2-chloropyridin-4-yloxy)-2,5-difluorophenyl]-N'-[4-fluorophenyl]cyclopropane-1,1-dicarboxamide 
• 1345847-79-1 N-(4-(2-acetamidopyridin-4-yloxy)-2,5-difluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 1345847-81-5 N-(5-chloro-4-(2-chloropyridin-4-yloxy)-2-fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 1345847-83-7 N-(4-(2-acetamidopyridin-4-yloxy)-5-chloro-2-fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 1345847-89-3 N-(4-(2-(2-(dimethylamino)acetamido)pyridin-4-yloxy)-2,5-difluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 1345847-91-7 N-(4-(2-acetamidopyrimidin-4-yloxy)-2,5-difluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 1345847-93-9 N-(4-(2-(cyclopropanecarboxamido)pyridin-4-yloxy)-2,5-difluorophenyl)-N’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 
• 1345847-95-1 N-(2,5-difluoro-4-(2-propionamidopyridin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 

Relevant articles and documents

Methylpyrazole derivatives as RET inhibitor

The invention relates to a methylpyrazole derivative as an RET inhibitor, in particular to a compound as shown in a formula (I), a stereoisomer and pharmaceutically acceptable salt thereof, a preparation method and a pharmaceutical composition thereof. The compound of the formula (I) can be used for preventing or treating diseases mediated by abnormal RET activity.

Preparation method of broad-spectrum anti-cancer drug kimatinib (by machine translation)

The preparation method is simple, the reaction conditions are mild . the reaction conditions are mild, the intermediate stability is good, the side reaction: is less likely to occur, and the preparation method is very suitable for industrial production: a

Preparation method of Cabozantinib

The invention belongs to the field of pharmaceutical chemistry, and relates to a preparation method of Cabozantinib. The preparation method comprises following steps: 4-halogenated-6, 7-dimethoxyquinoline is reacted with 4-aminophenol to prepare a compoun